ABOUT THIS CONFERENCE
This two-part event provides a
forum in which discovery biologists and protein engineers can come together to
discuss next-generation strategies and technologies that will allow antibody
therapeutics directed against membrane proteins, particularly GPCRs, ion
channels and transporters, to advance into the clinic and beyond.
The first conference in the
set, Therapeutic Antibodies for Membrane Targets, will discuss the
fundamental challenges associated with GPCR and ion channel target families,
and offer a set of case studies of therapeutics directed at specific GPCR, ion
channel and transporter targets. An additional session explors the advantages
and challenges associated with targeting membrane proteins with antibody
fragments, nanobodies and other emerging protein formats.
SUGGESTED EVENT PACKAGE:
September 23: Practical Aspects of Structure-Based Drug Discovery with GPCRs Short Course 2
September 23: Production and Presentation of Integral Membrane Proteins for Antibody Discovery Short Course 7
September 24-25: Antibodies Against Membrane Protein Targets Conference Part One
September 25-26: Antibodies Against Membrane Protein Targets Conference Part Two
Day 1 | Day 2 | Download Brochure
Tuesday, September 24
7:00 am Registration and Morning Coffee
8:10 Chairperson’s Opening Remarks
Christopher Koth, Ph.D., Senior
Scientist, Structural Biology, Genentech
8:15 FEATURED PRESENTATION: Probing GPCR Dynamics Using
Genetically-Encoded Unnatural Amino Acids
Thomas P. Sakmar, M.D., Richard M.
& Isabel P. Furlaud Professor, Laboratory of
Chemical Biology & Signal Transduction, The Rockefeller University
8:45 Conformationally Sensitive
Camelid Antibodies to Stabilize GPCR-G Protein Complexes
Roger Sunahara, Ph.D., Assistant Professor
of Pharmacology, University of Michigan
9:15 LY2951742, an Antibody to Calcitonin
Gene-Related Peptide (CGRP) for Prevention of Migraine Headaches
David S. Grayzel, M.D., CEO,
Arteaus TherapeuticS
9:45 Grand Opening Coffee Break in the Exhibit Hall with
Poster Viewing
10:45 Nanobodies for the Structural
and Functional Characterization of GPCR Transmembrane
Signaling: From Structure to Function to Drugs
Jan Steyaert, Ph.D., Head of
Department, Structural Biology, Vrije University
Brussels, Belgium
11:15 Antibodies Against Difficult Targets: How to Tackle G-Protein Coupled ReceptorS
Stefanie Urlinger, Ph.D., Director,
Research & Development, MorphoSys AG
11:45 Monoclonal Antibodies Against Endothelin
A and B Human GPCR Subtypes
Frederic Ducancel, Ph.D., Head of
Laboratory, Institute of Biology and Technology, Saclay,
Atomic Energy Commission, France
12:15 pm Preclinical and Clinical Experience with PRO 140, a
Humanized Anti-CCR5 Antibody for the Treatment and Prevention of HIV
Richard Trauger, Ph.D., CSO,
CytoDyn
12:45 A Novel Regulatory Role of a Humanized Anti-CCR4
Antibody in Cancer Immunotherapy
DeKuan Chang, Ph.D., Research
Fellow, Cancer Immunology & AIDS, Dana-Farber Cancer Institute
1:15 LUNCHEON PRESENTATION: New Era of GPCR Drug Discovery: Multi-Pathway Screening Technologies
Elizabeth R. Quinn, Ph.D., Director, LeadHunter Discovery Services, DiscoveRx Corporation
2:15 Chairperson’s Opening Remarks
2:20 Isolation of Antibody Fragments and Alternative Scaffolds
from in vivo and in vitro Sources Against Membrane Protein Targets
Hilmar Ebersbach, Ph.D., Lab Head,
Antibody Generation, NIBR Biologics Center, Novartis Institutes for
BioMedical Research, Switzerland
2:50 Rapid Identification and Characterization of
Fabs for Structural Analysis of Membrane Proteins
Charles S. Craik, Ph.D., Professor
of Pharmaceutical Chemistry, Pharmacology, Biochemistry and Biophysics, University
of California, San Francisco
3:20 Sponsored Presentation (Opportunity Available)
3:50 Refreshment Break in the Exhibit Hall with Poster Viewing
4:30 A Bi-Specific Centyrin
Targeting EGFR and c-Met Inhibits Cellular Signaling through Avidity
Kristen M. Picha, Ph.D., Director,
Biology, Centyrex, Johnson & Johnson Ventures,
Janssen PharmaceuticalS
5:00 Nanobodies as Highly Specific
Antagonists and Agonists of the P2X7 Ion Channel
Friedrich Koch-Nolte, Ph.D., Professor, Immunology, Molecular
Biology, University Medical Center Hamburg, Germany
5:30 Interactive Breakout Discussion Groups
6:30 Welcome Reception in the Exhibit Hall with Poster Viewing
7:30 Close of Day
Day 1 | Day 2 | Download Brochure